"Aquadex provides aquapheresis, a form of extracorporeal ultrafiltration to reduce fluids, primarily for patients with congestive heart failure (CHF), and particularly when diuretics are not effective. CHF is a leading cause for hospitalization in the United States, particularly for individuals aged 65 and over. The patent-protected technology is FDA 510K market cleared and CE marked for both inpatient hospital and outpatient clinic use and has been successfully used on over 60,000 patients to date. The product is manufactured in Brooklyn Park, Minnesota."
SHC Price at posting:
2.5¢ Sentiment: Hold Disclosure: Held
